Which Biotech Companies Are Turning the Tables on Patent Cliffs?

       Which Biotech Companies Are Turning the Tables on Patent Cliffs?

  PR Newswire

  LONDON, January 14, 2013

LONDON, January 14, 2013 /PRNewswire/ --

Although much has been made over pharmaceutical company profits tumbling due
to loss of exclusivity for blockbuster drugs, companies in the biotechnology
technology industry have been turning in strong quarterly earnings, and also
have a number of exciting new products that are scheduled to soon hit the
market. Companies like Dendreon Corporation (NASDAQ:DNDN), Sequenom Inc.
(NASDAQ:SQNM) and Celgene Corporation (NASDAQ:CELG) have been garnering
investor attention due to their most recently released financial results,
among other things, while Arena Pharmaceuticals Inc. (NASDAQ:PGNX) and
Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) have been in the spotlight
surrounding progress in bringing new drugs to market. In an attempt to save
lives and come out with the next big thing, companies have been focusing their
research and development on a number of specific areas, including cancer and
obesity. With the research and development costs associated with bringing a
new product to market remaining high, companies that are financially sound
provide investors with a safer option, as the risk of not having enough
capital to complete the process is reduced. See how companies in this industry
have grown over the past years and how they are expected to perform in 2013.
Talk to our analysts, sign up now for free at

http://www.stockcall.com/register   

One company that has been performing well from a financial perspective is
Dendreon Corp. The company newly announced that preliminary fourth quarter net
product revenues are anticipated to come in at $85.5 million, a marked
sequential improvement. The company's community accounts also rose in
quarter-over-quarter comparisons, with oncology growing 4% and urology jumping
25% overall. Heightened interest for PROVENGEĀ®, the company's autologous
cellular immunotherapy for the treatment of prostate cancer, also bodes well
for the company moving forward. Find out more about Dendreon Corp. by talking
to our financial experts today at

http://www.stockcall.com/register

Both Sequenom and Celgene have also been attracting investor attention of
late. Sequenom newly posted its Initial 2012 Performance Results, with total
revenue of approximately $89 million, an increase of about 59% when compared
year-over-year. The life sciences company stated that it saw a strong response
to its MaterniT21 Plus test, in part due to a broader acceptance of the test
by the OB/GYN physician community. Celgene's unaudited year-over-year 2012
financial results were also impressive. The company stated that total net
product sales are expected to be $5.4 billion, an impressive 15% year over
year increase. Celgene also saw prosperity out of its REVLIMID offering, as
quarterly net product sales in the fourth quarter alone were expected to
exceed $1.0 billion. The company has stated that it expects net sales of
REVLIMID in 2013 to be between $4.1 billion and $4.2 billion. Get our
financial professionals' take on Celgene's latest quarterly earnings by
registering at

http://www.stockcall.com/register

Elsewhere in the industry, companies have been taking strides to get new
products to market. Those that receive FDA approval stand to benefit greatly,
and interested investors may want to keep a close eye on how pipeline products
are developing for individual companies. Arena Pharmaceuticals has been
progressing nicely in this regard, as its anti-obesity product BELVIQ, which
has already received FDA approval, is expected by some to launch within the
first three months of this year. The potential for the drug is immense given
the obesity problem in the U.S. and other nations and the limited number of
FDA approved anti-obesity drugs. The company has high hopes for BELVIQ, and
recently announced a marketing and supply agreement with Ildong
Pharmaceuticals Co. Ltd., by which Ildong will have exclusive rights to market
and distribute BELVIQ in South Korea, subject to regulatory approval from the
Korea Food and Drug Administration. Progenics has also been active recently,
as MedImmune newly stated that it has signed an in-licensing agreement with
Progenics for its Clostridium difficile late-stage preclinical program. Is
Arena Pharmaceuticals the stock you are planning to add to your portfolio?
Check with our analysts if it is a worthy addition by signing up at

http://www.stockcall.com/register

With biotechnology firms zeroing in on new treatments and products, the
industry looks poised for an exciting 2013. How individual companies will
perform will depend on their ability to get new products to market and make
existing ones competitive, but for now analysts at StockCall.com believe the
outlook is positive. If you want to build on this trend, ask our analysts
about the industry and the companies mentioned in this article by visiting us
and sign up for free as a member at

http://www.stockcall.com/register

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

http://www.stockcall.com

Contact: William T. Knight, e-mail: info@stockcall.com, tel: +1(646) 396-9857
(9:00 am EST - 01:30 pm EST)